IBEF: March 23, 2021
Virchow Biotech, based in Hyderabad, and the Russian Direct Investment Fund (RDIF) announced a collaboration on Monday to manufacture up to 200 million doses of the Sputnik V vaccine in India.
According to a joint statement from RDIF and Virchow Biotech, the technology transfer is expected to be completed in the second quarter of 2021, followed by full-scale commercial production of Sputnik V. Virchow Biotech's capabilities would enable the global supply of Sputnik V to RDIF's international partners.
RDIF CEO, Mr. Kirill Dmitriev said, “The deal with Virchow Biotech is a significant step toward enabling full-scale domestic manufacturing of the vaccine in India and supplying our global partners.”
The efficacy of Sputnik V is 91.6%, as reported by data published in the Lancet.
Virchow Biotech MD, Mr. Tummuru Murali said, “We are delighted to have signed a collaboration agreement with RDIF to manufacture the Sputnik V coronavirus vaccine. Virchow's demonstrated capabilities in large-scale drug substance production should help achieve the vaccine's global demand.”
On March 19, 2021, RDIF and India's Stelis Biopharma announced a collaboration to manufacture and supply a minimum of 200 million doses of Sputnik V COVID-19 vaccine.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.